# Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia

> **NCT02910102** · PHASE2 · COMPLETED · sponsor: **Axovant Sciences Ltd.** · enrollment: 38 (actual)

## Conditions studied

- Alzheimer's Disease
- Dementia With Lewy Bodies
- Parkinson's Disease Dementia

## Interventions

- **DRUG:** RVT-101 35 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02910102
- **Lead sponsor:** Axovant Sciences Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10
- **Primary completion:** 2017-11
- **Final completion:** 2017-11
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2020-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02910102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02910102, "Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02910102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*